Fukuwa Clinic

Chūōku 104-0031

0 studies enrolling now · 11 studies all time

What they study most

Alzheimer Disease, Alzheimer's Disease, Atherosclerotic Cardiovascular Disease (ASCVD), Chronic Obstructive Pulmonary Disease (COPD), Elevated Lp(a), Hypertension, Moderate to Severe Asthma, Obesity, Overweight, Overweight or Obesity, Type 2 Diabetes

Studies at this site

• A Master Protocol for Orforglipron (LY3502970) in Participants With Obesity or Overweight With and Without Type 2 Diabetes — Running, not enrolling
• A Study of Orforglipron (LY3502970) in Participants With Obesity or Overweight and at Least One Weight-Related Comorbidity — Running, not enrolling
• A Study to Investigate the Effect of Lepodisiran on the Reduction of Major Adverse Cardiovascular Events in Adults With Elevated Lipoprotein(a) - ACCLAIM-Lp(a) — Running, not enrolling
• A Study to Evaluate the Efficacy and Safety Study of Povorcitinib in Participants With Inadequately Controlled Moderate to Severe Asthma — Running, not enrolling
• A Master Protocol for Orforglipron (LY3502970) in Participants With Hypertension and Obesity or Overweight: (ATTAIN-Hypertension Screening) — Running, not enrolling
• A Master Protocol Study of Orforglipron (LY3502970) in Participants With Hypertension and Obesity or Overweight (ATTAIN-Hypertension) GZL1 — Running, not enrolling
• A Master Protocol Study of Orforglipron (LY3502970) in Participants With Hypertension and Obesity or Overweight (ATTAIN-Hypertension) GZL2 — Running, not enrolling
• A Study to Evaluate Astegolimab in Participants With Chronic Obstructive Pulmonary Disease — Running, not enrolling
• A Study of Orforglipron (LY3502970) in Participants With Obesity or Overweight and Type 2 Diabetes — Running, not enrolling
• A Donanemab (LY3002813) Study in Participants With Preclinical Alzheimer's Disease (TRAILBLAZER-ALZ 3) — Running, not enrolling
• A Study of Remternetug (LY3372993) in Early Alzheimer's Disease (TRAILRUNNER-ALZ 3) — Running, not enrolling